Abstract
Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy
Volume: 7 Issue: 1
Author(s): I. Olcay
Affiliation:
Abstract: Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Export Options
About this article
Cite this article as:
Olcay I., Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (1) . https://dx.doi.org/10.2174/187152308783769131
DOI https://dx.doi.org/10.2174/187152308783769131 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Signaling Function of the IL-13Rα2 Receptor in the Development of Gastrointestinal Fibrosis and Cancer Surveillance
Current Molecular Medicine Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics Extraction of Triacylglycerols and Fatty Acids Using Supercritical Fluids - Review
Current Analytical Chemistry Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Review: Technegas - 99mTc-Metal Core Graphite Nanoparticles for Pulmonary Ventilation Imaging
Current Radiopharmaceuticals Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19
Protein & Peptide Letters Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews The Potential of PDE4 Inhibitors in Respiratory Disease
Current Drug Targets - Inflammation & Allergy Delivery of Contraceptives to Men: Lesson from Other Therapeutic Drugs
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology PIP3 Regulation as Promising Targeted Therapy of Mast-Cell-Mediated Diseases
Current Pharmaceutical Design Dual Acting Antihistaminergic Agents
Mini-Reviews in Medicinal Chemistry Defense-related Proteins from Chelidonium majus L. as Important Components of its Latex
Current Protein & Peptide Science Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Immunomodulatory Effects of Soybeans and Processed Soy Food Compounds
Recent Patents on Food, Nutrition & Agriculture Update of Asthma Assessment in Children
Current Pediatric Reviews TFF (Trefoil Factor Family) Peptides and their Potential Roles for Differentiation Processes During Airway Remodeling
Current Medicinal Chemistry Pharmacological Inhibitors of Cysteinyl Leukotrienes Biosynthesis: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cytokines as Targets in Chronic Obstructive Pulmonary Disease
Current Drug Targets Ligand-Based Homology Modeling as Attractive Tool to Inspect GPCR Structural Plasticity
Current Pharmaceutical Design